Aspivix: Funding, Investors & Team (Sep 2026)
We are a Swiss-based medical device firm focused on women's health that is creating cutting-edge gynecological equipment. Our flagship product, CarevixTM, is the first suction cervical stabilizer in the world with clinical evidence that it reduces pain and bleeding during transcervical operations frequently carried out in gynecology, such as IUD insertion. The tenaculum, a device created over a century ago and regarded as the gold standard of care, has an effect on more than 90 million women globally. Carevix is presently being created. Commercial release is anticipated for 2H2022 in selected European regions and the USA. Our mission at Aspivix is to modernize gynecology today.
Aspivix has raised $5.6M across 3 funding rounds on record, the most recent an undisclosed round of $560k announced in Jun 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aspivix Company Profile and Key Stats
Latest funding round on record: Jun 2024.
Aspivix Funding Rounds
1 of 3 rounds was announced without a disclosed amount and is excluded from the total.
Aspivix raised $5.0M in a Series A announced in Nov 2022.
1.3 years later, an undisclosed round was announced in Feb 2024 with no disclosed amount.
4 months later, an undisclosed round of $560k was announced in Jun 2024.
Aspivix Founders and Leadership Team
Contact details for the Aspivix team: 1 of 1 has an email address on file.
Start 14-day free trial →Aspivix Funding Compared to Other Biotechnology Startups
Aspivix's latest round of $560k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aspivix in Biotechnology and Renens
Companies Similar to Aspivix
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Aspivix Funding FAQs
What does Aspivix do?
We are a Swiss-based medical device firm focused on women's health that is creating cutting-edge gynecological equipment. Our flagship product, CarevixTM, is the first suction cervical stabilizer in the world with clinical evidence that it reduces pain and bleeding during transcervical operations frequently carried out in gynecology, such as IUD insertion. The tenaculum, a device created over a century ago and regarded as the gold standard of care, has an effect on more than 90 million women globally. Carevix is presently being created. Commercial release is anticipated for 2H2022 in selected European regions and the USA. Our mission at Aspivix is to modernize gynecology today.
How much funding has Aspivix raised?
Aspivix has raised $5.6M across 3 rounds on record. The most recent is an undisclosed round of $560k announced in Jun 2024.
When did Aspivix last raise funding?
Aspivix's most recent funding round on record is an undisclosed round of $560k, announced in Jun 2024.
Who founded Aspivix?
FundedIQ lists Mathieu Horras (Founder) at Aspivix.
Where is Aspivix headquartered?
Aspivix is based in Renens, Vaud, Switzerland.
How many employees does Aspivix have?
Aspivix is in the 11-50 employee band.
How does Aspivix's funding compare to other Biotechnology startups?
Aspivix's latest round of $560k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Aspivix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aspivix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.